Article Name China
HighTide’s HTD1801 Shows Long-Term Benefits for Type 2 Diabetes in Phase III Studies
The 52-week data from these two Phase III clinical trials demonstrate the durability of response and highlight the comprehensive long-term clinical benefits of HTD1801 in patients with T2DM
31st October, 2025
Everest Medicines Acquires Exclusive Greater China and Other Asian Country Rights to VIS-101
This collaboration marks Everest’s strategic expansion into ophthalmology, a high-potential “blue-ocean” therapeutic area
31st October, 2025
MGI Tech announces licensing agreement with Swiss Rockets AG
The strategic partnership is set to fully unlock the patent value and productisation capabilities of CoolMPS, complementing MGI's tried-and-true StandardMPS technology
29th October, 2025
Fangzhou Unveils AI + Weight Management Innovation at China’s Weight Management Symposium in Beijing
China has designated weight management as a national health priority, integrating it into the Healthy China 2030 strategy through a series of government-led initiatives
24th October, 2025
Everest Medicines Enrols First Patient in Global Trial of mRNA Cancer Vaccine EVM14
EVM14, an off-the-shelf therapeutic mRNA cancer vaccine, was developed based on Everest Medicines' proprietary mRNA platform
15th October, 2025
Smartee launches Sleep Aligner Combining Anti-Snoring Therapy with Teeth Alignment
The Smartee Sleep Aligners Series addresses this challenge through digitally customised clear aligners with a dual-splint locking system that advances the mandible while distributing occlusal forces to stabilise the jaw
13th October, 2025
PHASE Scientific Launches World’s Largest Clinical Study on Urine-Based Cervical Cancer Screening in China
The 17,000-woman study, led by Peking University Shenzhen Hospital, sets three world records and integrates PHASiFY™ DNA concentration technology with AI-powered diagnostics to advance scalable, non-invasive screening in line with WHO’s 2030 elimination goals.
23rd September, 2025
PHASE Scientific Launches Urine-Based Cervical Cancer (HPV) Screening Clinical Study
The study applies PHASE Scientific’s proprietary PHASiFY urine-based DNA concentration technology
22nd September, 2025
China’s Healthcare Investment Climate: Rebalancing Global and Local Innovation
Yang Huang, Head of China Healthcare Research at J.P. Morgan, unpacks how favourable policies, demographic shifts, and global collaborations are shaping the future of biopharma and medtech investment in China.
19th September, 2025
Fangzhou Unveils XingShi LLM to Advance AI-Driven Chronic Disease Management
XS LLM integrates multimodal capabilities, image and speech recognition, natural language processing, large-scale medical knowledge storage, and reasoning
15th September, 2025
Fangzhou Secures 2nd National Science Foundation Project Approval
The study will examine the influence of human-AI collaboration models on consumer adoption
03rd September, 2025
Hua Medicine Strengthens Financial Position to Support Sustainable Growth
One-Time Income Release and Improved Gross Margins Strengthen Financials
01st September, 2025
Yunkang Group's 2025 Interim Net Loss Narrows, Demonstrating Strong Operational Resilience
AI Empowers Medical Institution Alliances to Strengthen New Quality Productive Forces
01st September, 2025
Fosun Unlocks Adaptive Growth Through Pharma Innovation and Globalisation
In the first half of 2025, Fosun’s four core subsidiaries generated a total revenue of RMB63.61 billion
01st September, 2025
Essex Bio-Technology Drives Growth and Innovation
Revenue up 5.8 per cent to HK$876.5 million, Profit up 3.8 per cent to HK$163.4 million
01st September, 2025
Neusoft Medical Systems Launches China's First Photon-Counting CT with NMPA Approval
Photon-counting CT (PCCT) is considered a breakthrough in next-generation imaging
28th August, 2025
Foxconn Technology invests $30Mn in Robocore to expand into Medical and Elderly Care Robotics Market
Projects 5X Revenue Growth by 2028, Accelerates Global Market Leadership and Paves the Way for IPO
20th August, 2025
NMPA accepted Essex biologics license application for EB12 20145P HLX04 O for wet age related macular degeneration
Phase 3 AURA 1 trial meets primary endpoint paving way for new treatment option in China
15th August, 2025
Medtech Special
© 2023 MM Activ Sci-Tech Communications. All rights reserved | Disclaimer